Dr. Davis brings to Biosion over 30 years of experience in the biotech and pharmaceutical industries. Dr. Davis joined Biosion from Frontage Laboratories, Inc., where he served as Chief Business Officer, leading the company to a very successful IPO in May of 2019. Prior to Frontage, Dr. Davis worked with Johnson & Johnson where he served as Vice President and Head of Biologics Development Sciences in the Janssen BioTherapeutics (JBIO) division of Janssen R&D, LLC since 2001. During his tenure in J&J, Hugh and his team were instrumental in the development and approval of many biologic therapies including Remicade, Stelara, Simponi, Sylvant, Darzalex and Tremfya.  Prior to J&J, Hugh led the Pharmacodynamics & Exploratory Research Laboratory in the Clinical Pharmacology Unit at Glaxo SmithKline from 1996 to 2001. 

Dr. holds a Ph.D. degree in Biochemistry from Villanova University and completed Post-Doctoral training at Centocor, Inc. (now Janssen R&D, LLC) where he patented the characterization of tumor biomarker for ovarian cancer, CA125.